Research News
View articles by month and year
-
Chemo During Pregnancy Appears Safe for Mother and Child
A study supports other research that suggests chemotherapy during pregnancy doesn't have harmful effects on the baby.
-
Xgeva Better Than Zometa at Reducing Risk of Bone Problems in Women with Metastatic Disease
Research suggests that Xgeva is better than Zometa at reducing the risk of bone complication and improves quality of life more in women diagnosed with metastatic breast cancer that has spread to the bones.
-
Docs Need to Consider Quality of Life When Assessing Lymphedema
A study strongly suggests that considering a person's quality of life as well as reducing swelling is very important to managing lymphedema.
-
Research Suggests How Metastatic Cancer Becomes Resistant to Chemotherapy
A very early study on cancer cells in petri dishes in the lab has found that a type of cell called a fibroblast also is damaged by chemotherapy. Damaged fibroblasts make a protein called WNT16B that may help metastatic cancer cells become resistant to chemotherapy and grow.
-
Most Older Women Seem to Benefit from Radiation After Lumpectomy
Contrary to current treatment guidelines, a new study suggests that radiation therapy after lumpectomy may help most older women diagnosed with early-stage, hormone-receptor-positive breast cancer avoid a later mastectomy.
-
Injectable Herceptin Shows Promise
A study suggests that an injectable form of Herceptin works just as well as and is as safe as the standard IV form of Herceptin to treat HER2-positive, early-stage breast cancer before surgery.
-
Fertility Drugs Seem to Affect Breast Cancer Risk in Younger Women
A study suggests that women younger than 50 who use fertility drugs to successfully conceive a child may see their risk of breast cancer go up. But this higher risk is about the same as the average woman's risk.
-
Accelerated Radiation May Be as Good as Standard Schedule to Lower DCIS Recurrence Risk
Research suggests that a shorter, higher-dose radiation schedule after lumpectomy to remove DCIS may reduce recurrence risk just as much as a standard radiation treatment schedule.
-
Afinitor Approved to Treat Advanced-Stage, Hormone-Receptor-Positive Disease
Afinitor has been approved to be used in combination with Aromasin to treat advanced-stage, hormone-receptor-positive, HER2-negative breast cancer in postmenopausal women that has already been treated with Femara or Arimidex.
-
Aromatase Inhibitors Seem Less Effective in Obese Women
A small study found that while obese women diagnosed with early-stage, hormone-receptor-positive breast cancer who took Arimidex and Femara had lower estrogen levels than before they started treatment, their estrogen levels were still more than double those of women at a healthy weight.
